Clopidogrel (Mistro, Ogravia)
Clopidogrel
Pharmacare limited û woodmead
Registration
- Applicant
- Pharmacare limited û woodmead
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Mistro EACH TABLET CONTAINS CLOPIDOGREL BISULFATE EQUIVALENT TO CLOPIDOGREL 75,0 mg | Not listed | 41014641/8.2/0146 | Registered | Not determined | None |
| Ogravia 75 MG EACH TABLET CONTAINS CLOPIDOGREL HYDROGEN SULPHATE EQUIVALENT TO CLOPIDOGREL 75,0 mg | 75 mg | 45028845/8.2/0288 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S3: Clopidogrel
Consolidated Schedules 06 July 2026, line 3342
S2: Aspirin
- the treatment of children or adolescents; and
- the prophylaxis of cardiovascular disease in adults (S0)
Consolidated Schedules 06 July 2026, lines 1616 to 1620
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate
Drag to rotate. Structure from PubChem CID 60606.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.